Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines

J Immunol. 2002 Mar 15;168(6):2930-8. doi: 10.4049/jimmunol.168.6.2930.

Abstract

The role of secretory IgA in conferring cross-protective immunity was examined in polymeric (p)IgR knockout (KO) mice immunized intranasally with different inactivated vaccines prepared from A/PR/8/34 (H1N1), A/Yamagata/120/86 (H1N1), A/Beijing/262/95 (H1N1), and B/Ibaraki/2/85 viruses and infected with the A/PR/8/34 virus in the upper respiratory tract (RT)-restricting volume. In wild-type mice, immunization with A/PR/8/34 or its variant (A/Yamagata/120/86 and A/Beijing/262/95) vaccines conferred complete protection or partial cross-protection against infection, while the B-type virus vaccine failed to provide protection. The protection or cross-protection was accompanied by an increase in the nasal A/PR/8/34 hemagglutinin-reactive IgA concentration, which was estimated to be >30 times the serum IgA concentration and much higher than the nasal IgG concentration. In contrast, the blockade of transepithelial transport of dimeric IgA in pIgR-KO mice reduced the degree of protection or cross-protection, in parallel with the marked increase in serum IgA concentration and the decrease in nasal IgA concentration (about 20 and 0.3 times those in wild-type mice, respectively). The degree of the reduction of protection or cross-protection was moderately reversed by the low but non-negligible level of nasal IgA, transudates from the accumulated serum IgA. These results, together with the absence of the IgA-dependent cross-protection in the lower RT and the unaltered level of nasal or serum IgG in wild-type and pIgR-KO mice, confirm that the actively secreted IgA plays an important role in cross-protection against variant virus infection in the upper RT, which cannot be substituted by serum IgG.

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Administration, Intranasal
  • Animals
  • Antibodies, Viral / biosynthesis
  • Antibodies, Viral / chemistry
  • Cholera Toxin / administration & dosage
  • Cholera Toxin / immunology
  • Female
  • Hemagglutinin Glycoproteins, Influenza Virus / administration & dosage
  • Hemagglutinin Glycoproteins, Influenza Virus / immunology
  • Immunization, Secondary
  • Immunoglobulin A / biosynthesis
  • Immunoglobulin A / chemistry
  • Immunoglobulin G / biosynthesis
  • Immunoglobulin G / chemistry
  • Influenza A virus / immunology*
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / immunology*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • Mice, Transgenic
  • Orthomyxoviridae Infections / genetics*
  • Orthomyxoviridae Infections / immunology*
  • Orthomyxoviridae Infections / prevention & control
  • Receptors, Polymeric Immunoglobulin / deficiency*
  • Receptors, Polymeric Immunoglobulin / genetics*
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / prevention & control
  • Vaccines, Combined / administration & dosage
  • Vaccines, Combined / immunology

Substances

  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Immunoglobulin A
  • Immunoglobulin G
  • Influenza Vaccines
  • Receptors, Polymeric Immunoglobulin
  • Vaccines, Combined
  • Cholera Toxin